Patients with a persistent form of diabetic macular edema, which causes swelling of the retina, appear to do better with a prescribed drug over laser therapy, the long-preferred treatment for the eye condition.

Scientists continue to search for next-step treatment options for people living with lung cancer. A combination of chemotherapy agents may be an alternative for some folks.

Cancer tumors survive and grow in part because of a network of blood vessels they build. This is called angiogenesis . Scientists can't fully explain the process, but are beginning to understand its origins. Previously, a series of experimental results published from New York and Italy showed evidence that the blood vessel growth in the brain cancer glioblastoma was cancer-based growth, rather than normal blood vessels growing to feed tumors. Angiogenesis inhibitors such as Avastin ( bevacizumab ) would only be effective against normal blood vessels, and researchers believed that t...

The capacity of cancer to outsmart its opponents is legendary. That's why therapies have to be multifaceted. New research shows that going after two targets hits the bulls-eye in knocking the lights out of tumors.

As if the drug shortages hitting the cancer world aren't bad enough, there are now reports of fake drugs on the market!

A single drug can have many uses. This is certainly the case for Avastin ( bevacizumab ), which is widely used to treat a number of different kinds of cancer. The drug may protect against the spread of yet another.

One of the most exciting frontiers in oncology is discovering molecular behavior that responds to existing drug therapies. Just such a discovery has been made regarding a deadly form of brain cancer.

Medicare has announced it will pay for Provenge ( sipuleucel-T ) to treat metastatic prostate cancer. This drug extends the life of patients by about four months.

In an unprecedented appeals hearing, the US Food and Drug Administration (FDA) has not changed its mind.  An FDA panel voted that the drug Avastin no longer be approved for treating late-stage breast cancers.

Even though a U.S. Food and Drug Administration (FDA) panel has voted to no longer approve Avastin ( bevacizumab ) for treating late-stage breast cancers, Medicare has indicated it will continue to pay for the drug.